%PDF-1.4
%
77 0 obj
<>
endobj
74 0 obj
<>
endobj
142 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T11:31:48Z
2024-03-29T08:30:36-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T08:30:36-07:00
application/pdf
Heather
2003-192.april
uuid:4eef271a-1dd2-11b2-0a00-6c0827fd5800
uuid:4eef271c-1dd2-11b2-0a00-6a0000000000
endstream
endobj
63 0 obj
<>
endobj
64 0 obj
<>
endobj
78 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 53 0 R/Type/Page>>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
38 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
164 0 obj
[168 0 R]
endobj
165 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.0199 Tc 0.46271 Tw 10 0 0 10 54 713.1616 Tm
(including metabolic and inflammatory articular dis-)Tj
-0.00011 Tc 0 Tw 0 -1.2 TD
(orders)Tj
0 Tc 0.02499 Tw 6.5 0 0 6.5 78.9829 704.4616 Tm
(23\32025 .)Tj
0.0141 Tc 0.36079 Tw 10 0 0 10 66 689.1616 Tm
[(It can be concluded that despite HAAR)59.5 (T)74.1 (, muscu-)]TJ
-0.00011 Tc 0.0385 Tw -1.2 -1.2 Td
(loskeletal manifestations remain relatively common in HIV)Tj
0.05811 Tw T*
[(infected individuals although the clinical spectrum of HIV)91.7 (-)]TJ
0.11259 Tw T*
(associated rheumatic disease has changed, with septic and)Tj
0.0658 Tw T*
(malignant involvement being the most common manifesta-)Tj
0.02499 Tw T*
(tions noted. )Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 595.1616 Tm
[(1.)-875.1 (Berman )54.8 (A, Espinoza LR, Diaz JD, et al. Rheumatic manifestations)]TJ
1.675 -1.25 Td
[(of human immunodeficiency virus infection. )54.8 (Am J Med)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1988;85:59-64.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (W)39.8 (inchester R, Bernstein DH, Fischer HD, Enlow R, Solomon G.)]TJ
1.675 -1.25 Td
[(The co-occurrence of Reiter)-37 (\325)55.1 (s syndrome and acquired )]TJ
T*
[(immunodeficiency)64.8 (. )54.8 (Ann Intern Med 1987;106:19-26.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Buskila D, Gladman DD, Langevitz P)110.7 (, et al. Rheumatologic )]TJ
1.675 -1.25 Td
(manifestations of infection with the human immunodeficiency)Tj
T*
(virus. Clin Exp Rheumatol 1990;8:567-71.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Medina-Rodriguez F)79.7 (, Guzman C, Jara LJ, et al. Rheumatic )]TJ
1.675 -1.25 Td
(manifestations in human immunodeficiency virus positive and)Tj
T*
[(negative individuals. )54.8 (A)-220.1 (study of 2 populations with similar risk)]TJ
T*
(factors. J Rheumatol 1993;20:1880-6.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV)91.7 (-AIDS.)]TJ
1.675 -1.25 Td
(Baillieres Best Pract Res Clin Rheumatol 2000;14:579-93.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (T)69.9 (ebas P)110.7 (, Henry K, Nease R, et al. )17.7 (T)35 (iming of antiretroviral therapy)64.8 (.)]TJ
1.675 -1.25 Td
(Use of Markov modeling and decision analysis to evaluate the)Tj
T*
[(long-term implications of therapy)64.8 (. )54.8 (AIDS 2001;15:591-9.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Asherson RA, Shoenfeld )36.8 (Y)128.9 (. Human immunodeficiency virus )]TJ
1.675 -1.25 Td
(infection, antiphospholipid antibodies, and the antiphospholipid)Tj
T*
(syndrome. J Rheumatol 2003;30:214-9.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (V)128.9 (olberding P)91.7 (A. )54.8 (Advances in the medical management of patients)]TJ
1.675 -1.25 Td
[(with HIV)91.7 (-1 infection: an overview)64.8 (. )54.8 (AIDS 1999;13 Suppl 1: S1-9. )]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Lavalle C, )54.8 (Aguilar JCD, Pena F)79.7 (, et al. Reduction in hospitalization)]TJ
1.675 -1.25 Td
[(costs, morbidity)64.8 (, disability)64.8 (, and mortality in patients with )54.8 (AIDS)]TJ
T*
[(treated with protease inhibitors. )54.8 (Arch Med Res 2000;31:515-9.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Murphy EL, Collier )54.8 (AC, Kalish LA, et al. Highly active )]TJ
2.175 -1.25 Td
(antiretroviral therapy decreases mortality and morbidity in patients)Tj
T*
[(with advanced HIV)-257.3 (disease. )54.8 (Ann Intern Med 2001;135:17-26.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Berman )54.8 (A, Cahn P)110.7 (, Perez H, et al. Prevalence and characteristics of)]TJ
2.1381 -1.25 Td
(rheumatic manifestations in patients infected with human )Tj
T*
[(immunodeficiency virus under)17.7 (going antiretroviral therapy)64.8 (. )]TJ
T*
(J Rheumatol 1997;24:2492.)Tj
30.825 54.921 Td
[(12.)-875.1 (Stein M, Davis P)110.7 (. Rheumatic disorders in Zimbabwe: a prospective)]TJ
2.175 -1.25 Td
[(analysis of patients attending a rheumatic disease clinic. )54.8 (Ann)]TJ
T*
(Rheum Dis 1990;49:400-3.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Davis P)110.7 (, Stein M, Latif )54.8 (A, Emmanuel J. )54.8 (Acute arthritis in)]TJ
2.175 -1.25 Td
(Zimbabwean patients: possible relationship to human )Tj
T*
(immunodeficiency virus infection. J Rheumatol 1989;16:346-8. )Tj
-2.175 -1.25 Td
[(14.)-875.1 (Njobvu P)110.7 (, Mc Gill P)110.7 (, Kerr H, et al. Spondyloarthropathy and human)]TJ
2.175 -1.25 Td
(immunodeficiency virus infection in Zambia. J Rheumatol)Tj
0 Tc 0 Tw T*
(1998;25:1553-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Itescu S. Dif)17.7 (fuse infiltrative lymphocytosis syndrome in human)]TJ
2.175 -1.25 Td
[(immunodeficiency virus infection: a Sjogren\325)54.8 (s-like disease. Rheum)]TJ
T*
[(Dis Clin North )54.8 (Am 1991;17:99-1)36.8 (15.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Munoz Fernandez S, Cardenal )54.8 (A, Balsa )54.8 (A, et al. Rheumatic )]TJ
2.175 -1.25 Td
(manifestations in 556 patients with human immunodeficiency virus)Tj
T*
[(infection. Semin )54.8 (Arthritis Rheum 1991;21:30-9.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Casado E, )17.7 (T)69.9 (ena X, Olive )54.8 (A. HIV)-257.3 (infection-associated rheumatic)]TJ
2.175 -1.25 Td
(syndromes. Clin Exp Rheumatol 1999;17:633.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Calabrese LH. )17.7 (The rheumatic manifestations of infection with the)]TJ
2.175 -1.25 Td
[(human immunodeficiency virus. Semin )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1989;18:225-39.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Reveille JD. )17.7 (The changing spectrum of rheumatic disease in human)]TJ
2.175 -1.25 Td
[(immunodeficiency virus infection. Semin )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;30:147-66.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (V)110.8 (assilopoulos D, Chalasani P)110.7 (,)-0.1 ( Jurado RL, )17.7 (W)79.9 (orkowski K, )54.8 (Agudelo)]TJ
2.175 -1.25 Td
(CA. Musculoskeletal infections in patients with human )Tj
T*
(immunodeficiency virus infection. Medicine 1997;76:284-94.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Casado E, Olive )54.8 (A, Holgado S, et al. Musculoskeletal )]TJ
2.175 -1.25 Td
(manifestations in patients positive for human immunodeficiency)Tj
T*
(virus: correlation with CD4 count. J Rheumatol 2001;28:802-4.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Farizo K, Buehler J, Chamberland L, et al. Spectrum of disease in)]TJ
2.175 -1.25 Td
(persons with human immunodeficiency virus infection in the)Tj
T*
[(United States. JAMA)-220.2 (1992;267:1798-805.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Powderly )17.7 (WG. Sorting through confusing messages: the art of)]TJ
-0.0298 Tw 2.175 -1.25 Td
[(HAAR)59.7 (T)74 (.)-0.1 ( AIDS )-54.8 (2002;31:S3-S9.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Orenstein R. Presenting syndromes of human immunodeficiency)]TJ
2.175 -1.25 Td
(virus. Mayo Clin Proc 2002;77:1093-102.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Florence E, Schrooten )17.7 (W)91.8 (,)-0.1 ( )17.7 (V)110.8 (erdonck K, Dreezen C, Colebunders R.)]TJ
2.175 -1.25 Td
(Rheumatological complications associated with the use of indinavir)Tj
T*
[(and other protease inhibitors. )54.8 (Ann Rheum Dis 2002;61:82-4.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(746)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 57.75 396.47 -10.83 re
f*
0.5 w
109.25 57.75 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
57 0 obj
<>stream
8;Z\7$#[X7%+G5@W:+P:9T$QT/F>@2_H*Ig,?#j6VsZWir2[%HoJ>M(HWopM9)lrp
H0;\NjI0q155r^eBo=ao.Wd'#Kd*SWnF=(Ckp#e(.a@g3:kWrH5rHI>)(l2M>YWkg
<8`[N_&[9LlZEi,8&jX/DfEJ\b]B5)4CRYoT%h@C^66E?*CkB1+$B#LcE?GH#;sUk
mdWHe_/%:6,&+E(^*!5VR;2hm&nYio,rN<8"%RH)qBMjS3Ge%]q&=s:$)ZG)!oD]K
D#E!Ug!iQph%[rdFeMV^b6jf\/M*'?X0UJ%oQpd9lRNOF?/1&`Dg4SqY:HS```P@.
X-F*o0.ud+<"hba<-:l"C2Njkj4>Dg!P%V&1*4@8obJN"#
ai.+K:T3$c.q#oO8WL3!;IF$f6#Ke8P'Op<;Co.FA\)<^7-P"@M14K4'jMjtg>A0%
AYBC"ldsUBSRnbW%
endstream
endobj
61 0 obj
[/Indexed/DeviceRGB 255 60 0 R]
endobj
60 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
129 0 obj
<>
endobj
85 0 obj
<>
endobj
41 0 obj
<>
endobj
80 0 obj
<>
endobj
116 0 obj
<>
endobj
147 0 obj
<>
endobj
81 0 obj
<>
endobj
108 0 obj
<>stream
HT{PSg˽(BF֮ͭTA XʂD$AH y y#j}GA[UKֱnĝٕc9s;7\pwZ}D*/ڤ}}b,m!smgm94IGΩ_澉<|fhHKj;]\8Eb%
v%+>Z:+Y0Yݩ+R9)j,6Z9{d$;^+gcrqlv1+!"6$L,
=ޒ(B-f=ِŲXVb+C0IHD,g!-bј؇4[Gc[oZۏ=gJZcUDL&܈uryu'г|M$ffҫl]lS)S^I;;v"Xafsv`ZUӿnfkQg:V3WZ)KЪRCMfE4AI̤3u/84A1[ )#^#3)MFI&S*es)uux}4H>,& 2hUf'hZr2أ51Grjmgu/T]OzXO sh..&`&W)9^}I5?FA4/ftUhLWVTdFe'DK'w%FUPo#p)ͅQ)h/?h>[q'_"CNȪHY/jk,_yUR.w;2vG5p*|V!3#9_x'NQ[tq-nkl^ˌVjUX6F>u6)Mҙ&73
0GpfgSDWpvzMtf@$kSQ LX"`! B?9AVjE^-F(aRl
R+C]O˟{Zں-(v)Q4<`8>Ȑ|Y遲
imqQsGLvZ#k9 ZAɦwȱ_ȯ),k!i5Ye{y@{]>5;0Ren^L\})W*FoZ΅Z{*O>y5bAYZF^zu4pE>{#do߾{מw?|fdcwv!5iaYf4-b`ÕMzEtpF#8{+3f7*
zy2CAHPRh駗&YrFNq˜BFSoP&4^@vԛ!X饊.Z@xf ;Dqg[k.V4nF$ʊkruU\=vd!LT ӝ}KoJnpڵbu;r4-4n*{9`$S.LV.a_ѶRGUxDĠ?yEpAeeS
ӣxmbU4[{j=,؟i}o jroGuH>p?7W`W@05_9ԗEѻBdGrkEhyytGR2_S_O:`lW1$ XxȼwhN#T?hI% -DSېEʅԏ1)%ț+뇵d%ؠhz6%9N_f-cjbj)ȩ ?)^Jo
*jF^T\赹pjq_(8ؐ,4"$̝b JH6 rryolA1$_[Ҕtl1owze_X{ƫ53
Ccc릕4 S"Q]+
X$r[܄ܸ@ $0AAD@0EmTvW;U0_'h:u>^C>y-O5B!/C/fKyuŨȾ(Ǩ8aWs,Uױn9St tQQyAKkpg"[8pSѡ>l;Ƃ!LE晄_!oЗR&Zj/%TIc"Cgz"}!,Tuisl/2E2J)'A@TDYֆv"
*ۃV~Z;]56Z5jf(3D@ q
M
z.>tF.r-!)0\ʧʷYAl$ԙ&ĨFMn!f5L#Hbl8YdfH9jvꌺ/[];F@ \V;?:< iOgpvTm|oж`abҦC[t͂G'u suM?ukQ`w;}|,0q*>0TƲRTZWZҐ:=so"\,Η
xh(I`mC~ă)ƗM8AE]iۦu'ƽXs.zmxz R\ 4LQ6x[%"(xe4UVnlZӰ%,똭1k#&.;n*1LdYT
ēLtXfoQWz;xcA]w!()oF!x@!w\NMIzϦbdd쉺ct=lq[0XPqܔ'rdG5BА+1L%ZZhc<,(Y Ԑ
e 5߬/ڪMV,Fhܫf
#BwzeD.k/'8^{qqڧkRbBM!"SI5Qur_)g
#M:sXh(Pan"Vېg4a<(4Mûx38q('HsdYtq5"pҩuں[-}`vbqK_RKI?Leu0:\VW&Oi-"Z
~aO4c=|> -ЃR(AoFM&%PPĕqE=v0K1k.D~s~
(/(.". #;%U-(jJjqBQAaZ6ʯ˾Rf=މamh|WAW1<\J{䖇uZ>"~Ńs8K$eW,tn_]R_0s|d#-L]k#yueO+e0orW%NB{Ը2̸ٖ}+ۍ"U]4Rn5+&Bt 4#6`QE}Y|FV({daL5kUsb]IJ^#1K V}sĜLX@bb?sX`ݟXmCZqdZs&*==}YĒ TM`si_gm?X;`cћ`EQwQ% VW('W]>K*@M^7ܬГ_!?ƫ>:7w\5x+2L%,Lllc۳g{ý0lnc`PĄ)ff&KK~*λw}?ЏNkXT\r?A,wѶ2b_U&U
Fx^_߃LXߘB